229 related articles for article (PubMed ID: 35636054)
1. NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
Zhao D; Zarif M; Eladl E; Capo-Chichi JM; Smith AC; Atenafu EG; Tierens A; Minden MD; Schuh A; Chang H
Leuk Res; 2022 Jul; 118():106869. PubMed ID: 35636054
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
[TBL] [Abstract][Full Text] [Related]
4. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
5. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic abnormalities in
Fu W; Huang A; Xu L; Peng Y; Gao L; Chen L; Chen J; Tang G; Yang J; Ni X
Leuk Lymphoma; 2022 Aug; 63(8):1956-1963. PubMed ID: 35227153
[No Abstract] [Full Text] [Related]
7. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.
Kaseb H; Visconte V; Socha DS; Crane GM; Durkin L; Cook JR; Maciejewski JP; Hsi ED; Rogers HJ
Genes Chromosomes Cancer; 2023 Oct; 62(10):573-580. PubMed ID: 36959701
[TBL] [Abstract][Full Text] [Related]
9. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
10. Myeloid sarcoma with
Ramia de Cap M; Wu LP; Hirt C; Pihan GA; Patel SS; Tam W; Bueso-Ramos CE; Kanagal-Shamanna R; Raess PW; Siddon A; Narayanan D; Morgan EA; Pinkus GS; Mason EF; Hsi ED; Rogers HJ; Toth L; Foucar K; Hurwitz SN; Bagg A; Rets A; George TI; Orazi A; Arber DA; Hasserjian RP; Weinberg OK;
Leuk Lymphoma; 2023 May; 64(5):972-980. PubMed ID: 36960680
[TBL] [Abstract][Full Text] [Related]
11. [The Mutated Gene Sequenced by NGS and the Correlation of Their Coexistent Mutual Exclusiveness in NPM1 Mutated Acute Myeloid Leukemia].
Dai L; Wang ZL; Qiu GQ; Wu YC; Zhang XW; Xing SS; Wang B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1733-1740. PubMed ID: 34893102
[TBL] [Abstract][Full Text] [Related]
12. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
Kansal R
Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
[TBL] [Abstract][Full Text] [Related]
13. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
14. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
15. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
16. Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Kumar R; Minden MD; Chang H
Biol Blood Marrow Transplant; 2020 Nov; 26(11):1995-2000. PubMed ID: 32712325
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
[TBL] [Abstract][Full Text] [Related]
18. PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
Liu J; Qin W; Wang B; Wang Z; Hua H; Zhou F; Jia Z; Wu P; Chao H; Lu X
Leuk Res; 2022 Jul; 118():106859. PubMed ID: 35617714
[TBL] [Abstract][Full Text] [Related]
19. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
Simonetti G; Mengucci C; Padella A; Fonzi E; Picone G; Delpino C; Nanni J; De Tommaso R; Franchini E; Papayannidis C; Marconi G; Pazzaglia M; Perricone M; Scarpi E; Fontana MC; Bruno S; Tebaldi M; Ferrari A; Bochicchio MT; Ghelli Luserna Di Rorà A; Ghetti M; Napolitano R; Astolfi A; Baldazzi C; Guadagnuolo V; Ottaviani E; Iacobucci I; Cavo M; Castellani G; Haferlach T; Remondini D; Capozzi F; Martinelli G
Leukemia; 2021 Oct; 35(10):2813-2826. PubMed ID: 34193978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
